Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel

Shachor-Meyouhas, Yael; Hussein, Khetam; Dabaja‐Younis, Halima; Szwarcwort-Cohen, Moran; Almog, Ronit; Weissman, Avi; Mekel, Michal; Hyams, Gila; Horowitz, Nethanel A.; Gepstein, Vardit; Netzer, Itamar; Saban, Hagar Cohen; Petersiel, Neta; Tarabeia, Jalal; Halberthal, Michael

doi:10.1016/j.cmi.2021.11.014

Cited by 9 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No dependency with the antibodies’ level was found with gender. This is in contrast with what Shachor-Meyouhas et al [ 80 ] showed in their analysis where the male sex was identified as a risk factor for lower antibody level in an observational timeline of 3 months after the second shot. The strength of our analysis is that it extended over 9 months after the second shot.…”

Section: Discussioncontrasting

confidence: 91%

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

et al. 2022

View full text Add to dashboard Cite

The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of the Polyclinic of Bari to identify the relationship of antispike titers with blood type, sex, age, and comorbidities. This prospective observational study (RENAISSANCE) had as its primary endpoint the assessment of serologic response to BNT162b2 at three blood titers: the first at 60 days after the second dose (3 February 2021); the second titer at 75 days after the first titer; and the third titer at 130 days after the second titer. Out of 230 enrolled staff members, all responded excellently to the mRna Pfizer (BNT162b) vaccine. Only one patient, 40 days after the second dose (3 February 2021), was positive on the swab control performed on 15 March 2021, although completely asymptomatic, and was negative on the subsequent molecular swab performed on 30 March 2021. All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispike IgG level above 500 BAU/mL at the first antispike protein essay (60 days after the second dose on 3 April 2021); at the second titer (75 days after the first titer on 20 June 2021), 4 (1.7% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL; at the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose), 37 (16.1% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL. The data analysis demonstrated that patients belonging to blood group 0, regardless of their rhesus factor, showed the strongest level of antibodies compared to the other groups. No dependency was found between low antibodies level and sex or age. Molecular swab controls were performed every 15th of the month continuously. However, the enrolled patients’ activity was at high risk because they carried out medical activities such as dental and surgical as well with droplets of water vaporized by the effect of turbines, piezosurgery. The vaccination campaign among health workers of the Policlinico of the University of Bari “Aldo Moro” led to an excellent serological response and the complete absence of COVID-19 incident cases, so the antibody response was excellent. The COVID-19 vaccine booster shot should be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient.

show abstract

Section: Discussioncontrasting

confidence: 91%

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Thus, in August 2021, in Israeli HCW, the surge of SARS-CoV-2 infections, mostly by Delta variant, appeared in 21.4% individuals that received only the two-dose regimen while the rate in the HCW group that have received a booster was only 0.7%. Therefore, in this group, a booster vaccination indicates substantial protection by a third vaccine dose 13 while previous studies in the same country have shown that at 3 months most HCWs still had measurable antibodies 14 . Nevertheless, in the same country at 5 months, a third dose of the BNT162b2 mRNA vaccine is effective in protecting subjects against severe COVID-19, compared with the subjects receiving only two doses 15 .…”

Section: Introductionmentioning

confidence: 60%

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Zurac

Vlădan

Dincă

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Waning of the immune response upon vaccination in SARS-CoV-2 infection is an important subject of evaluation in this pandemic, mostly in healthcare workers (HCW) that are constantly in contact with infected samples and patients. Therefore, our study aimed to establish the specific humoral response of specific IgG and IgA antibodies upon vaccination, during the second year of pandemic and evaluating the booster shot with the same vaccine type. A group of 103 HCW with documented exposure to the virus were monitored for specific IgG and IgA levels prior to vaccination, after the first vaccination round, during the following 8 months and after the booster shot with the same vaccine type. After 8 months post-vaccination the humoral response in both IgG and IgA decreased, 2.4 times for IgG, and 2.7 times for IgA. Although the antibodies levels significantly decreased, no documented infection was registered in the group. After the booster shot, the entire group, displayed IgG increased levels, immediately after booster followed by the increase in specific IgA. IgG levels post-second round of vaccination are statistically higher compared to the first round, while IgA is restored at the same levels. Within the vaccination or booster routine for a multiple waves’ pandemic that is generating new virus variants, populational immunity remains an important issue for future implementation of prevention/control measures.

show abstract

“…Studies have shown that age, gender, underlying diseases, and immunosuppressive treatment all affect neutralizing antibodies' induction and levels. [40][41][42] Therefore, the above factors need to be taken into account in booster vaccination and vaccine dosage selection. 43,44 Countries and regions with good epidemic prevention and control, such as China, are mainly infected by imported COVID-19 cases.…”

Section: The Objectives Of Covid-19 Booster Vaccinationmentioning

confidence: 99%

“…Since neutralizing antibodies in patients previously infected with SARS‐CoV‐2 have been at a high level, the need for a booster might be delayed. Studies have shown that age, gender, underlying diseases, and immunosuppressive treatment all affect neutralizing antibodies' induction and levels 40–42 . Therefore, the above factors need to be taken into account in booster vaccination and vaccine dosage selection 43,44 …”

Section: The Objectives Of Covid‐19 Booster Vaccinationmentioning

confidence: 99%

Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety

Meng

Mao

2022

Journal of Medical Virology

View full text Add to dashboard Cite

At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies.

show abstract

Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel

Cited by 9 publications

References 14 publications

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers

Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety

Contact Info

Product

Resources

About